Home  |  News  |  Events  |  References  |  Terms of Use  |     

Point of Care applications in clinical trials are referenced in these published articles

  1. The Paragon Investigators. International, Randomized, Controlled, Trial of Lamifibian (a Platelet Glycoprotein IIb/IIIa Inhibitor), Heparin, or Both in Unstable Angina. Circulation. 1998;97:2386-95
  2. Hertzberg V, Chimowitz M, Lynn M, Chester C, Asbury W, Cotsonis G. Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study. Clinical Trials. 2008;5(1):23-30
  3. Albers GW, Diener HC, et al. Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. JAMA. 2005;293:690-98
  4. Rao SV, Melloni C, et al. Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Trial. Circulation. 2010;121:1713-21
  5. Lincoff AM, Bittl JA, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention REPLACE-2 Randomized Trial. JAMA. 2003:289;853-63
  6. Francis CW, Berkowitz SD, et al. Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. NEJM. 2003;349;1703-12
  7. Schulman S, Kearon C, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Embolism. NEJM. 2009;361:2342-52
  8. Granger CB, Alexander JH, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. NEJM. 2011;365:883-91
  9. Solomon SD, Uno H, et al. Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. NEJM. 2010; 363:1146-55
  10. Patel MR, Mahaffey KW, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. NEJM. 2011;365:981-92
  11. Bang H, Park JJ. Blinding in Clinical Trials: A Practical Approach. The Journal of Alternative and Complementary Medicine. 2012;18:1-3
  12. Bang H, Flaherty SP, Kolahi J, Park J. Blinding assessment in clinical trials: A review of statistical methods and a proposal of blinding assessment protocol. CRRA. 2010;27(2):42-51
  13. Ridker PA, Goldhaber SZ, et al. Long Term, Low Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM. 2003;348:1425-34
  14. Lopes RD, Alexander JH, et al. Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOLE) trial: Design and rationale. AHJ. 2010;159(3):331-339
  15. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008;52:1128-33
  16. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116;2923-32
  17. Becker R, Berkowitz SD, et al. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. AHJ. 2010;159:340-7.e1
  18. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).AHJ. 2010;160:635-41.e2